Skip Navigation


Rheumatology Advance Access originally published online on January 7, 2009
Rheumatology 2009 48(4):327-329; doi:10.1093/rheumatology/ken454
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
48/4/327    most recent
ken454v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bukhari, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bukhari, M.
Related Collections
Right arrow Osteoporosis and Metabolic Bone Disease
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

The National Osteoporosis Guideline Group's new guidelines: what is new?

M. Bukhari1

1University Hospitals of Morecambe Bay, NHS Trust, Royal Lancaster Infirmary, Lancaster and Clinical Sciences, University of Liverpool, Liverpool, UK

Correspondence to: M. Bukhari, Department of Rheumatology, Royal Lancaster Infirmary, Ashton road, Lancaster LA1 4RP, UK. E-mail: marwan.bukhari@mbht.nhs.uk

The first 10% of the full text of this article appears below.

Introduction

The importance of osteoporosis (OP) to the health economy is widely documented [1]: with costs of fractures alone of £1.73 billion, the ageing population also will lead to a doubling of this estimated cost. Recent advances in the literature regarding the diagnoses and management of OP have occurred. Although there have been Royal College of Physicians (RCP) guidelines published in 1999, 2000 and 2002 [2–4] and National Institute for Healthcare and Clinical Excellence (NICE) guidances and the new final appraisal determination document from NICE [5–7], they have not been updated with recent advances including the newly developed World Health Organization FRAXTM data (www.shef.ac.uk/frax), which give a 10-yr fracture risk assessment and explains how it fits in the treatment paradigm. Additionally, newer treatments including zolendronate are not included. Other groups not included in current guidance are men or women receiving glucocorticoid . . . [Full Text of this Article]

New issues discussed in the guidance

How to define and assess OP
Assessment of fracture risk
Strategies for OP prevention and treatment
Prevention and treatment
Case finding
Recommendations

Conclusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?